trending Market Intelligence /marketintelligence/en/news-insights/trending/xqvu5b3a1g5w9fpjqfxvyg2 content esgSubNav
In This List

Mylan, Dr. Reddy's win FDA nod for generics of Indivior's opioid dependency drug

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Mylan, Dr. Reddy's win FDA nod for generics of Indivior's opioid dependency drug

The U.S. Food and Drug Administration approved the first generic versions of Indivior PLC's Suboxone film, which dissolves under the tongue and is used to treat opioid dependence.

Suboxone is a combination of buprenorphine and naloxone. The agency granted approvals to Mylan NV unit Mylan Technologies Inc. and Dr. Reddy's Laboratories Ltd. unit Dr. Reddy's Laboratories SA to market buprenorphine and naloxone sublingual film in multiple strengths.

FDA Commissioner Scott Gottlieb said the regulator plans to promote the development of better drugs for opioid use disorder and facilitate market entry of generic versions of approved drugs to help ensure broader access.

"The FDA is also taking new steps to address the unfortunate stigma that's sometimes associated with the use of opioid replacement therapy as a means to successfully treat addiction," Gottlieb said.